Popular search terms:
Search Results Label
64 results found-
Seqirus | About Influenza
Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.
https://www.seqirus.com/expertise/influenza -
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/news/seqirus-receives-canadian-approval -
Seqirus | Influenza Expertise
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.com/expertise -
Seqirus | Latest News
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/news/new-data-demonstrate-that-fluad-reduces-hospitalization-risk-for-adults-65 -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.com/news/seqirus-releases-first-shipment-for-2019-2020-season -
Seqirus Presents New Clinical Data Reinforcing MF59
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/news/seqirus-presents-new-clinical-data-reinforcing-mf59 -
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses
https://www.seqirus.com/news/seqirus-presents-scientific-data-comparing-circulating-influenza-b-viruses -
Seqirus opens new Centre of Excellence in Amsterdam
Seqirus opens new Centre of Excellence in Amsterdam
https://www.seqirus.com/news/seqirus-opens-new-centre-of-excellence-in-amsterdam -
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/news/seqirus-begins-shipping-2017-2018-influenza-vaccines -
Seqirus Cellbased Influenza Vaccine Nears European Approval
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.
https://www.seqirus.com/news/seqirus-cellbased-influenza-vaccine-nears-european-approval